{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Overman MJ"],"funding":["American Cancer Society","NCI NIH HHS","National Institutes of Health"],"pagination":["139-144"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5834085"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(1)"],"pubmed_abstract":["Background
Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC.Patients and methods
The primary objective was Response Evaluation Criteria in Solid Tumors version 1.1 response rate. Eligibility included Eastern Cooperative Oncology Group performance status 0/1, refractory disease, and SBA or CIMP-high metastatic CRC. Nab-paclitaxel was in"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer."],"pmcid":["PMC5834085"],"funding_grant_id":["P30 CA016672","127343-RSG-15-068-01-TBG"],"pubmed_authors":["Adam L","Kopetz S","Azad N","Vilar E","Overman MJ","Wang J","Wolff R","Pisanic TR","Fogelman D","Dasari A","Raghav K","Morris J","Shroff R","Karunasena E","Kee B","Eng C"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.","description":"Background
Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC.Patients and methods
The primary objective was Response Evaluation Criteria in Solid Tumors version 1.1 response rate. Eligibility included Eastern Cooperative Oncology Group performance status 0/1, refractory disease, and SBA or CIMP-high metastatic CRC. Nab-paclitaxel was in","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jan","modification":"2025-04-19T15:17:39.04Z","creation":"2019-03-26T22:26:58Z"},"accession":"S-EPMC5834085","cross_references":{"pubmed":["29069279"],"doi":["10.1093/annonc/mdx688"]}}